Matricelf to Attend The Digital Spine & Pain Neuroscience Summit 2026 in Phoenix, Arizona

Rhea-AI Summary

Matricelf (OTC: MTRLF) will attend the Digital Spine & Pain Neuroscience Summit 2026 in Phoenix, AZ, Feb 26–Mar 1, 2026. The senior team will engage clinicians and researchers, present its personalized neural tissue regeneration platform, explore partnerships, and highlight ethical approvals and preclinical progress toward first‑in‑human studies.

Participation underscores Matricelf's focus on clinical translation and broader adoption of regenerative therapies for spinal cord injury.

PHOENIX and NESS ZIONA, Israel, Feb. 26, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company advancing personalized curative treatments for spinal cord injury, announced that it will attend the Digital Spine & Pain Neuroscience Summit 2026 (DSPN Spine Summit) being held in Phoenix, AZ between the February 26^th to March 1^st. The Summit is one of the premier global gatherings for clinicians, researchers, industry leaders, and innovators focused on spine care, neuroscience, and advanced therapeutic technologies.

The DSPN Spine Summit, featuring a comprehensive agenda of cutting edge scientific sessions, expert panels, and emerging technology showcases provides a unique forum for advancing collaboration across the spine and regenerative medicine community.

Matricelf at the Summit

Matricelf's senior team will participate in the Summit to:

• Engage with key opinion leaders, clinicians and researchers in spinal cord injury and regenerative medicine.
• Present the Company's personalized neural tissue regeneration platform and clinical development strategy.
• Explore strategic partnerships that could support clinical translation, commercialization and broader adoption of Matricelf's therapies.
• Highlight recent milestones, including ethical approvals and pre-clinical progress toward first in human studies.

Attending this conference reinforces Matricelf's commitment to advancing breakthrough regenerative therapies and enhancing outcomes for patients with paralysis due to spinal cord injury.

Statement from Management

Gil Hakim, CEO of Matricelf, said: "We are pleased to participate in the DSPN Spine Summit, where leading clinicians and innovators will convene to advance the future of spine care. This Summit is an invaluable opportunity to share our vision and engage with the global spine and neuroscience community as we move toward human clinical studies in the U.S."

About the DSPN Spine Summit

The Digital Spine & Pain Neuroscience Summit is a global event dedicated to the latest evidence based science, innovation, and technology in spine care and pain management. The Summit brings together multidisciplinary experts to drive collaboration, elevate standards of care and highlight advances that shape the future of the field.

About Matricelf Ltd.

Matricelf Ltd. (TASE: MTLF) is a regenerative medicine company developing a personalized autologous neural tissue platform intended to restore function in patients with spinal cord injury. By leveraging patient derived cells and proprietary tissue engineering technologies, the Company aims to advance regenerative therapies from laboratory to clinic.

Forward Looking Statements

This press release contains forward looking statements regarding Matricelf's participation at the Summit, clinical development plans, potential collaborations and future business prospects. Actual results may differ materially due to risks and uncertainties.

CONTACT INFO:
Gil Hakim
CEO
Matricelf
Tel: +972-52-5263351
GIL@MATRICELF.COM

 

View original content:https://www.prnewswire.com/news-releases/matricelf-to-attend-the-digital-spine--pain-neuroscience-summit-2026-in-phoenix-arizona-302698259.html

SOURCE Matricelf Ltd.

FAQ

When and where will Matricelf (MTRLF) attend the DSPN Spine Summit 2026?

Matricelf will attend the DSPN Spine Summit in Phoenix, AZ from February 26 to March 1, 2026. According to the company, the senior team will participate in sessions, panels, and networking to advance collaborations and clinical plans.

What will Matricelf (MTRLF) present at the DSPN Spine Summit 2026?

Matricelf will present its personalized neural tissue regeneration platform and clinical development strategy. According to the company, presentations will emphasize preclinical progress, ethical approvals, and steps toward first‑in‑human studies.

Does Matricelf (MTRLF) expect to announce clinical trial timelines at the DSPN Spine Summit?

The company will highlight preclinical progress and ethical approvals but did not announce definitive trial start dates. According to the company, the summit is for engagement and exploring partnerships that could support clinical translation.

How does Matricelf's (MTRLF) attendance affect investor visibility?

Attendance increases visibility with clinicians, KOLs, and potential partners, aiding clinical translation awareness. According to the company, senior leadership will use the summit to discuss commercialization and partnership opportunities relevant to investors.

Will Matricelf (MTRLF) seek partnerships at the DSPN Spine Summit 2026?

Yes. Matricelf plans to explore strategic partnerships to support clinical translation and commercialization. According to the company, meetings will focus on collaborations that could accelerate broader adoption of its therapies.

What did Matricelf CEO Gil Hakim say about the company's participation in DSPN Spine Summit 2026?

Gil Hakim said the summit is an invaluable opportunity to share Matricelf's vision and engage the global spine community. According to the company, participation supports progress as the company moves toward human clinical studies in the U.S.